Vitamin E for Extremely Preterm Infants
The purpose of this pilot trial is to test the safety and efficacy of administering one dose of vitamin E, via a tube into the stomach, to extremely preterm infants (less than 27 weeks gestation and less than 1000 grams birth weight). This pilot will examine whether a single dose of vitamin E will be absorbed into the infants' bloodstreams with resulting serum α-tocopherol level in the target range of 1-3 mg/dl.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Vitamin E
- drug: Placebo
Eligibility
Inclusion Criteria:
- Less than 27 completed weeks gestational age
- Birth weight less than 1,000 grams
- Inborn infants
Exclusion Criteria:
- Infant's treatment will be limited based on poor prognosis
- Umbilical cord or blood pH below 7.0
- Antenatally diagnosed brain abnormality, including hemorrhage
- Major congenital malformations, including those for which feeding is contraindicated
- Mother of infant enrolled in a clinical trial of vitamin E supplementation
- Mother of infant reports self administration of monovitamin supplements of vitamin E
during pregnancy or labor
- Infant has received supplemental vitamin E (except multivitamin additive in parenteral
nutrition or through enteral milk or formula feeds)
- Greater than four hours of age
Ages Eligible for Study
N/A - 4 Hours
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
M Bethany Ball
6507258342
I'm interested
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
